Cordyceps
Evidence Fact Sheet
Cordyceps (C. sinensis / C. militaris) is a fungal supplement studied for exercise, immune-marker, renal-adjunct and respiratory outcomes. Mechanisms involve cordycepin (an adenosine analog) and beta-glucan immune signaling. Human RCT evidence is mixed — positive and null exercise trials both exist. Typical research doses: Cs-4 mycelium 1-4 g/day. Legal DSHEA supplement; 0 EFSA-authorized claims.
Also known as: Cordyceps · Cordyceps sinensis · Ophiocordyceps sinensis · Cordyceps militaris · Cs-4 (CordyMax) · Cordycepin (3'-deoxyadenosine)
Overview
Cordyceps is a medicinal-fungus supplement sold mainly as two species — Cordyceps sinensis (often as the Cs-4 / CordyMax fermented mycelium) and Cordyceps militaris fruiting body, which is richer in the active compound cordycepin (3'-deoxyadenosine). In research models cordycepin acts as an adenosine analog that perturbs mRNA processing and engages adenosine-receptor and AMPK/mTOR energy-sensing signaling, while its beta-1,3-glucan polysaccharides activate innate immune cells (NK cells, macrophages) via TLR/Dectin-1 pathways. Human research doses cluster around 1-4 g/day of Cs-4 mycelium for exercise/fatigue and roughly 1-3 g/day of C. militaris extract for immune markers (renal-adjunct Chinese protocols used 3-6 g/day); species and standardization matter greatly and this is an educational reference, not a dosing instruction. Regulatory status: it is a legal dietary-supplement ingredient under DSHEA (structure/function claims only, no FDA-authorized health claim), has 0 EFSA-authorized health claims (both antioxidant and endurance applications were rejected), and in China is species-split — C. militaris fruiting body is an approved novel food while C. sinensis is managed as a TCM material. Wild C. sinensis carries a documented heavy-metal (arsenic) bioaccumulation risk.
Mechanism of Action
Cordycepin acts as a 3'-deoxyadenosine adenosine-analog that perturbs poly(A) polymerase / mRNA processing and engages adenosine-receptor signaling (research model) · AMPK activation with mTOR inhibition modulating energy metabolism, autophagy and cellular-senescence pathways (largely preclinical) · NF-kB suppression dampening TNF-alpha / IL-6 pro-inflammatory signaling (anti-inflammatory research model) · Cordyceps polysaccharide (beta-1,3-glucan) activation of NK cells / macrophages via TLR2 / TLR4 / Dectin-1 (innate-immunity research model) · NRF2 / antioxidant-response (Phase II enzyme) induction and ROS scavenging (preclinical)
Body systems: Mitochondrial & Cellular Energy · Immune System · Musculoskeletal · Respiratory & Mucosal Barrier · Renal & Urinary
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Cordyceps is not characterized as a treatment for any disease.
Exercise Capacity / Metabolic Threshold (Older Adults)
RCT supported- +10.5%metabolic threshold · p<0.02
- +8.5%ventilatory threshold
- n=20healthy elderly · 12 wk
In a 12-week placebo-controlled trial of Cs-4 (333 mg three times daily) in 20 healthy adults aged 50-75, the metabolic threshold rose 10.5% and the ventilatory threshold 8.5% versus placebo. Notably, VO2max itself did not change in either group — the benefit was on sub-maximal metabolic thresholds, not peak aerobic capacity. This is the positive side of a contradictory exercise literature.
Reported effect: Metabolic threshold +10.5% (0.83→0.93 L/min, p<0.02); ventilatory threshold +8.5% (1.25→1.36 L/min); n=20; no change in VO2max
“After receiving Cs-4 for 12 weeks, the metabolic threshold increased by 10.5% from 0.83 +/- 0.06 to 0.93 +/- 0.08 L/min (p < 0.02) ... the ventilatory threshold increased by 8.5% from 1.25 +/- 0.11 to 1.36 +/- 0.15 L/min ... No significant changes in VO2 max occurred in either treatment group.”
Source: PMID 20804368 · Chen 2010 · J Altern Complement Med
Aerobic Capacity / Endurance (Trained Cyclists)
Null / no benefit RCT supported- no effectVO2peak & time-trial
Honest negative: in 22 endurance-trained male cyclists, 5 weeks of CordyMax Cs-4 at 3 g/day produced no change in VO2peak and no difference in time-trial performance versus placebo. Together with the positive older-adult trial above, this shows the exercise evidence is genuinely contradictory and may depend on training status and population.
Reported effect: VO2peak unchanged (CS 59.1→57.1 ml/kg/min vs PLA 59.9→60.1); time trial 62.1 vs 61.4 min, not different; no effect concluded
“It is concluded that 5 weeks of CordyMax Cs-4 supplementation has no effect on aerobic capacity or endurance exercise performance in endurance-trained male cyclists.”
Source: PMID 15118196 · Parcell 2004 · Int J Sport Nutr Exerc Metab
Cell-Mediated / Innate Immune Markers (Healthy Adults)
RCT supported- n=39 vs 40C. militaris vs placebo
- 1.5 g/day4 weeks
- P=.0010NK-cell activity (NK200)
In healthy male adults, 1.5 g/day of ethanol-treated Cordyceps militaris for 4 weeks significantly raised NK-cell activity (NK200), lymphocyte proliferation, and the Th1 cytokines IL-2 and IFN-γ versus placebo. These are immune-response biomarkers in a healthy population, not a clinical disease outcome; 'boosts immunity' framing is avoided.
Reported effect: Greater increase vs placebo in NK200 (P=.0010), lymphocyte PI (P≤.0001), IL-2 (P=.0096), IFN-γ (P=.0126); n=39 active / 40 placebo, 1.5 g/day, 4 wk
“The C. militaris group showed a statistically significant greater increase in NK200 (P = .0010), lymphocyte PI (P ≤ .0001), IL-2 (P = .0096), and IFN-γ (P = .0126), compared with the basal level, than the placebo group.”
Source: PMID 26284906 · Kang 2015 · J Med Food
Renal-Function Markers (Chronic Kidney Disease · Adjunct)
Meta-analysis supported- 22 studies1746 participants
- -60.76 µmol/Lserum creatinine · MD
- -0.15 g/24h24h proteinuria · MD
A Cochrane review of 22 studies (1,746 participants) found that Cordyceps preparations, as an adjuvant to conventional medicine, were associated with lower serum creatinine, higher creatinine clearance, and reduced proteinuria in chronic kidney disease. Crucially the authors stress the evidence is low quality and no definitive conclusion can be drawn — this is an adjunct-to-medical-care research finding, not a standalone wellness claim.
Reported effect: Serum creatinine MD -60.76 µmol/L (95% CI -85.82 to -35.71, 14 studies/987); creatinine clearance MD +9.22 mL/min (95% CI 3.10-15.34); 24h proteinuria MD -0.15 g/24h (95% CI -0.24 to -0.05); 22 studies, 1746 participants; low quality of evidence
“Cordyceps preparations were found to significantly decrease serum creatinine (14 studies, 987 participants): MD -60.76 μmol/L, 95% CI -85.82 to -35.71) ... reduce 24 hour proteinuria (4 studies, 211 participants: MD -0.15 g/24 h, 95% CI -0.24 to -0.05) ... However, definitive conclusions could not be made because of the low quality of evidence.”
Source: PMID 25519252 · Zhang 2014 · Cochrane Database Syst Rev
Respiratory Function / COPD (Cordyceps-Derived Bailing Capsule)
Meta-analysis supported- 27 RCTsBailing capsule meta-analysis
- FEV1 · 6MWTreported improved (no pooled number)
A meta-analysis of 27 RCTs of Bailing capsule — a Cordyceps sinensis mycelium product — reported direction-consistent improvements in FEV1, FEV1/FVC, the 6-minute walk test, acute COPD attacks and quality of life. The published abstract gives only the direction of effect and the trial count; pooled effect sizes were not extractable from the abstract (they live in the forest plots), so effect size is not reported here. This is a disease-context adjunct finding, not a wellness claim.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“The meta-analysis of 27 RCTs showed significant improvements in the treatment group for forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, and the 6-min walk test (6MWT). Additionally, there was a marked reduction in acute COPD attacks and an improvement in quality of life.”
Source: PMID 39460586 · Ma 2024 · Pharm Biol
Dosage (research context · not a recommendation)
Cs-4 fermented mycelium 1-4 g/day in exercise/fatigue RCTs (renal-adjunct Chinese protocols used 3-6 g/day); C. militaris fruiting-body extract ~1-3 g/day in immune RCTs. DSLD US market: 48 products, median 1100 mg/day (range 125-2938 mg). Species/standardization matters greatly (C. militaris fruiting body is cordycepin-rich vs Cs-4 mycelium which is cordycepin-poor but RCT-backed). Educational reference, not a dosing instruction.
Regulatory Status · 4 Markets
- US · FDA
- Cordyceps sinensis and C. militaris extracts are legal dietary-supplement ingredients under DSHEA; structure/function claims only with the mandatory disclaimer; no FDA-authorized health/disease claim; FDA GRAS GRN = 0. DSLD lists 48 marketed products.
- EU · EFSA
- Marketable as a food supplement / traditional herbal product in some member states, but 0 EFSA-authorized health claims; both Art.13(1) applications were REJECTED — antioxidant (EFSA Journal 2010;8(10):1752) and exercise/endurance (EFSA Journal 2011;9(6):2247). Functional copy limited to ingredient-fact / mechanism description.
- CN · China
- Species-split: C. militaris fruiting body is an approved novel food (MOH 2009 No.3) usable in common and health food; C. sinensis is a TCM material managed under TCM-material rules, not common food.
- BR · ANVISA
- No Cordyceps-specific authorization; fungal-extract supplement ingredients require case-by-case ANVISA assessment and Cordyceps is not on the approved functional-claim positive list.
Safety
Generally well tolerated in clinical trials at typical doses (mild GI upset, dry mouth occasionally reported); no formal UL established. Mushroom/fungal-allergy contraindication. Immune-activation profile warrants caution in autoimmune disease and in organ-transplant / immunosuppressant patients. Wild Cordyceps sinensis carries a documented heavy-metal (arsenic) bioaccumulation risk — products should provide heavy-metal testing. Renal use is ADJUNCT to medical care, never a substitute. Species standardization (C. militaris vs Cs-4 mycelium vs wild C. sinensis) must be labeled. Not pregnancy/lactation safety-established.
Related
Goals: athletic-performance · longevity-stack
Lifestyles: athletic-performance · senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 20804368 · Chen 2010 · J Altern Complement Med — Exercise Capacity / Metabolic Threshold (Older Adults)
- PMID 15118196 · Parcell 2004 · Int J Sport Nutr Exerc Metab — Aerobic Capacity / Endurance (Trained Cyclists)
- PMID 26284906 · Kang 2015 · J Med Food — Cell-Mediated / Innate Immune Markers (Healthy Adults)
- PMID 25519252 · Zhang 2014 · Cochrane Database Syst Rev — Renal-Function Markers (Chronic Kidney Disease · Adjunct)
- PMID 39460586 · Ma 2024 · Pharm Biol — Respiratory Function / COPD (Cordyceps-Derived Bailing Capsule)
Frequently Asked Questions
1. Does Cordyceps actually improve exercise performance?
The human evidence is genuinely contradictory. A 12-week trial in 20 healthy older adults (Chen 2010, PMID 20804368) found Cs-4 raised the metabolic threshold 10.5% and ventilatory threshold 8.5% — but with no change in VO2max. In contrast, a 5-week trial in 22 trained cyclists (Parcell 2004, PMID 15118196) found no effect on aerobic capacity or endurance. Benefit may depend on training status and population, and EFSA rejected the endurance claim outright.
2. What's the difference between Cordyceps sinensis (Cs-4) and Cordyceps militaris?
They are different species. Cordyceps militaris fruiting body is rich in cordycepin (3'-deoxyadenosine) and was used in the immune-marker RCT (Kang 2015, PMID 26284906). Cs-4 / CordyMax is a fermented C. sinensis mycelium that is cordycepin-poor but backs most of the exercise/fatigue trials. Standardization and species labeling matter a great deal, and wild C. sinensis carries a documented heavy-metal (arsenic) bioaccumulation risk.
3. Is the kidney evidence strong enough to rely on?
No. The Cochrane review (Zhang 2014, PMID 25519252) pooled 22 studies / 1,746 participants and found Cordyceps, used as an adjuvant to conventional medicine, was associated with lower serum creatinine (MD -60.76 µmol/L) and reduced proteinuria — but the authors explicitly state the evidence is low quality and no definitive conclusion can be drawn. It is an adjunct-to-medical-care research finding, never a substitute for medical treatment.
4. What is the regulatory status of Cordyceps?
In the US it is a legal dietary-supplement ingredient under DSHEA, allowing structure/function claims only with the mandatory disclaimer and no FDA-authorized health claim. In the EU there are 0 EFSA-authorized health claims — both the antioxidant and the exercise/endurance applications were rejected. In China the species are split: C. militaris fruiting body is an approved novel food, while C. sinensis is managed as a TCM material.
Last evidence review: 2026-06-13